Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetShares Issued
Ratios

C4 Therapeutics (CCCC) Accumulated Depreciation & Amortization (2019 - 2025)

C4 Therapeutics' Accumulated Depreciation & Amortization history spans 7 years, with the latest figure at $10.8 million for Q4 2025.

  • For Q4 2025, Accumulated Depreciation & Amortization rose 16.68% year-over-year to $10.8 million; the TTM value through Dec 2025 reached $10.8 million, up 16.68%, while the annual FY2025 figure was $10.8 million, 16.68% up from the prior year.
  • Accumulated Depreciation & Amortization reached $10.8 million in Q4 2025 per CCCC's latest filing, up from $1.5 million in the prior quarter.
  • In the past five years, Accumulated Depreciation & Amortization ranged from a high of $10.8 million in Q4 2025 to a low of $448000.0 in Q1 2024.
  • Average Accumulated Depreciation & Amortization over 5 years is $5.1 million, with a median of $6.6 million recorded in 2021.
  • Peak YoY movement for Accumulated Depreciation & Amortization: skyrocketed 30.64% in 2021, then plummeted 94.78% in 2024.
  • A 5-year view of Accumulated Depreciation & Amortization shows it stood at $6.9 million in 2021, then grew by 17.45% to $8.1 million in 2022, then decreased by 4.43% to $7.8 million in 2023, then increased by 18.97% to $9.2 million in 2024, then grew by 16.68% to $10.8 million in 2025.
  • Per Business Quant, the three most recent readings for CCCC's Accumulated Depreciation & Amortization are $10.8 million (Q4 2025), $1.5 million (Q3 2025), and $1.1 million (Q2 2025).